LLY News and Press, Eli Lilly and Company From 03/06/24

2024-03-06 05:50:00 ET Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the fourth quarter of 2023 of Zepbound. Now another rival co...

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting N...

2024-03-05 14:48:29 ET Summary Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2...

2024-03-05 14:42:07 ET More on Amphastar Pharmaceuticals Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript A First Look At Amphastar Pharmaceuticals ...

2024-03-05 13:28:08 ET Summary Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupi...

2024-03-05 13:02:26 ET More on Eli Lilly Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Eli Lilly price target upped at UBS on GLP...

2024-03-05 09:53:00 ET Two of the biggest names in the pharmaceutical industry right now are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) . Each company is at the forefront of the red-hot weight-loss market due to their innovative roster of diabetes medications. Bo...

2024-03-05 07:30:03 ET More on Baxter, DaVita, etc. Baxter International Inc. Is A Buy (Technical Analysis) Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts Broyhill - Fresenius Medical Care: Correctly Focused On Increas...

2024-03-05 06:15:00 ET The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite being worth only $2.4 billion in 2022. Where should investors...

2024-03-04 06:25:00 ET Eli Lilly (NYSE: LLY) stock is on a tear. Buoyed by an investor frenzy over GLP-1 weight-loss drugs -- Lilly's own Zepbound in particular -- shares of the Indianapolis-based drugmaker are up 148% over the last 52 weeks, and have been setting new all-time highs...